CompareApprovedPhase III
Weight Loss
Tirzepatide vs Retatrutide
A comparison between an approved dual incretin drug and a phase 3 triple-agonist candidate.
Tirzepatide
Weight Loss
Weight loss, type 2 diabetes, dual GIP/GLP-1 agonist
1,942 PubMed references1,033 human-tagged
Retatrutide
Weight Loss
Weight loss, triple agonist (GLP-1/GIP/glucagon)
133 PubMed references86 human-tagged
Side-by-side
| Signal | Tirzepatide | Retatrutide |
|---|---|---|
| Core mechanism | GIP/GLP-1 dual agonism | GIP/GLP-1/glucagon triple agonism |
| Research maturity | Approved | Phase III pipeline |
| Public conversation | Experience, side effects, pricing, maintenance | Anticipation, trial watching, next-generation comparisons |
Sentiment Readout
Retatrutide hype is mostly pipeline anticipation, while tirzepatide discussion is grounded in approved use and real access friction.
Regulatory Context
Tirzepatide has approved products; retatrutide remains investigational.